# Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

Source: https://onco.cc/trials/nct07825753/  
OnCo record `nct07825753` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trastuzumab emtansine, trastuzumab deruxtecan, datopotamab deruxtecan, sacituzumab govitecan and other drugs in pancreatic cancer, run by Fudan University, not yet recruiting.

## Summary

Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer is a phase 2, interventional study registered as NCT07825753 by Fudan University, with a registry enrolment figure of 225 participants, started 2026-09-10 and due to reach its primary completion in 2027-09-01. Interventions recorded: Trastuzumab emtansine (T-DM1); Trastuzumab deruxtecan (T-DXd); Datopotamab deruxtecan (Dato-DXd); Sacituzumab govitecan (SG); Enfortumab vedotin (EV); Becotatug vedotin (MRG003); Izalontamab brengitecan (iza-bren / BL-B01D1); Mirvetuximab soravtansine (MIRV). Conditions listed: Advanced or Metastatic Pancreatic Adenocarcinoma; Advanced or Metastatic Breast Cancer (BC). Primary outcome: Objective Response Rate (ORR) as Assessed by RECIST 1.1. Pancreatic eligibility wording from the registry: "Histologically confirmed recurrent (unresectable) or metastatic advanced pancreatic cancer or breast cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: PROBE
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07825753
- Phase: 2
- Setting: An Umbrella Clinical Trial of Antibody/Peptide-Drug Conjugates Matched by Mass Spectrometry-Based Absolute Quantitation of Proteins in Locally Advanced or Metastatic Pancreatic or Breast Cancer
- Sponsor: Fudan University
- Enrolled: 225

## Sources

- ClinicalTrials.gov NCT07825753: https://clinicaltrials.gov/study/NCT07825753

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07825753.json